Actelion
Clinical trials sponsored by Actelion, explained in plain language.
-
One pill to rule them all? new combo therapy for PAH shows promise
Disease control CompletedThis study tested whether a single pill containing two drugs (macitentan and tadalafil) works better for pulmonary arterial hypertension (PAH) than taking either drug alone. 187 adults with PAH took part. The goal was to see if the combination pill improves blood flow in the lung…
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated May 26, 2026 11:27 UTC
-
New hope for rare lung disease: experimental drug shows promise
Disease control CompletedThis study tested an experimental drug called ACT-293987 in 43 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. The trial first checked how a single dose affects blood flow in the lungs, then compared the drug to a placebo…
Phase: PHASE2 • Sponsor: Actelion • Aim: Disease control
Last updated May 26, 2026 11:25 UTC
-
New hope for kids with rare lung condition: drug shows promise in major trial
Disease control CompletedThis study tested a drug called macitentan in 165 children with pulmonary arterial hypertension (PAH), a serious condition where blood pressure in the lungs is too high. The goal was to see how the drug works in the body, if it is safe, and if it helps control the disease better …
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New PAH pill shows promise in delaying disease worsening
Disease control CompletedThis study tested a drug called selexipag in over 1,100 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. The goal was to see if selexipag could delay the first time a patient's condition got worse or led to death, compared…
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated May 15, 2026 11:56 UTC